Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283486 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty
A Phase 2 study of Aging and Frailty, sponsored by TNF Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT05283486 is a Phase 2 study of Aging and Frailty that has completed, run by TNF Pharmaceuticals. The registered enrollment target is 40 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05283486, a Phase 2 study of Aging and Frailty, has completed, sponsored by TNF Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
Conditions Studied
Interventions
- DRUG MYMD-1 600MG
- DRUG MYMD-1 750mg
- DRUG MYMD-1 900mg
- DRUG MYMD-1 1050mg
- DRUG placebo 600mg
Study Locations (3)
Florida
- Clinical Research of West Florida, Inc - Clearwater
- Clinical Research of West Florida - Tampa
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2023-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05283486
The ClinicalTrials.gov registry entry for NCT05283486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The listed sponsor is TNF Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 5 interventions - of which MYMD-1 600MG is the first listed.
NCT05283486 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT05283486 about?
NCT05283486 is a clinical study titled "Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty". The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
What is the current status of trial NCT05283486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-02-01. Estimated completion is 2023-06-07.
What conditions does trial NCT05283486 study?
This clinical trial studies the following conditions: Aging, Frailty, Sarcopenia.
What interventions are being tested in trial NCT05283486?
The interventions under investigation include: MYMD-1 600MG (DRUG), MYMD-1 750mg (DRUG), MYMD-1 900mg (DRUG), MYMD-1 1050mg (DRUG), placebo 600mg (DRUG).
Who is sponsoring clinical trial NCT05283486?
This trial is sponsored by TNF Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283486 being conducted?
This trial has 3 study locations across Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Empagliflozin Reversal of Arterial StiffnEss in Aging
RECRUITING · Phase 2
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
Acetate and Age-associated Arterial Dysfunction
RECRUITING · Phase 2
-
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.